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Abstract Background: Maternal serum concentrations of
macrophage migration inhibitory factor (MIF) have
recently been reported to be elevated in cases with pre-
eclampsia. These ﬁndings may be important in increas-
ing our understanding of the underlying events leading
to the development of preeclampsia, as this cytokine is
also expressed in the placenta, where it has been shown
to possess immunemodulatory activities. For this reason
we attempted to independently verify this report.
Methods: Plasma levels of MIF were assessed by ELISA
in plasma samples collected from normal healthy male
and female blood donors (n=20 per group), as well as
healthy normal pregnant women in all three trimesters
of pregnancy (n=60). In addition, MIF levels were
examined from cases with mild and severe preeclampsia
(n=20 per study cohort) and matched normotensive
pregnancies (n=20). Results: MIF levels were found to
be elevated in pregnancy (median=10.1 ng/ml) when
compared to non-pregnant controls (median=1.7 ng/
ml). A moderate, but not signiﬁcant, elevation was
found to occur from the ﬁrst to the third trimester of
pregnancy. No signiﬁcant diﬀerence was found to occur
between the two preeclampsia study groups when com-
pared to the normotensive control group. Conclusions:
Our data suggest that circulatory MIF concentrations
are elevated throughout pregnancy, but are not further
increased in preeclampsia.
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Introduction
Migration inhibitory factor (MIF) was one of the ear-
liest cytokines to be described as a T-cell soluble factor
which inhibited random macrophage migration [1].
Human MIF consists of a peptide of 114 amino acids
which form a homotrimer. In the interim, MIF expres-
sion has been found in several other cell types, including
macrophages, neutrophils, anterior pituitary cells and
bronchial alveolar cells [2, 3].
The presence of MIF in the anterior chamber of the
eye has drawn particular interest [2], as in this instance
MIF was shown to possess distinct immunosuppressive
activities. This study showed that MIF hindered the
chemotaxis of neutrophils and macrophages, suppressed
T- and B-cell proliferation in vitro, and also prevented
the activation and lytic activity of NK cells. In this
manner, the presence of MIF in the eye assisted with the
establishment of a condition of immune privilege in this
vital tissue. In this context it has also been shown that
MIF may promote malignant cell transformation by
inhibiting tumour-speciﬁc immune responses and by
enhancing neovascularisation [3].
In this regard it is worth noting that pregnancy in-
volves an intricate balance of the maternal immune
system with the presence of a semi-allogeneic foreign
fetus, and has also been suggested to involve a state of
immune privilege, in that undesired inﬂammatory re-
sponses are actively suppressed in the placenta. Hence,
previous reports describing MIF activity in placental
extracts [4], its expression in chrorionic villi [5, 6] and
more recently by amniotic epithelial cells [7], may serve
to indicate that placental MIF expression may be
important for the maintenance of normal pregnancy.
In this context a recent report has indicated that
circulatory MIF concentrations are elevated under
conditions of preeclampsia [8]. As preeclampsia is
associated with an altered response of the maternal im-
mune system [9], it is possible that aberrant expression of
MIF may play a role in the development of this imbal-
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ance. For this reason we have sought to independently
verify that MIF concentrations are elevated in pre-
eclampsia.
Materials and methods
Samples from normal pregnancies
This study was approved by the Institutional Review
Board of the Canton of Basel, and written informed
consent was requested in all instances. For the recruit-
ment of maternal plasma samples from normal preg-
nancies, 60 samples were collected from normal healthy
pregnant women in the ﬁrst to third trimester
(range=11+3 to 38+1 weeks). Twenty samples were
also obtained from normal healthy female and male
blood donors (Swiss Red Cross, Basel, Switzerland).
Preeclampsia samples
For the analysis of cases with preeclampsia, we used a
study cohort which has previously been described [10,
11]. In the current study we used a subset of the initial
cohort, in which the preeclampsia study group now
consisted of 20 cases with the mild form and 20 cases
with the severe form of the disorder and 20 gestational
age-matched normotensive controls samples. Pre-
eclampsia was determined by a blood pressure of ‡140/
90 mmHg in two determinations 4 h apart or by a
diastolic blood pressure of ‡110 mmHg and an asso-
ciated proteinuria of ‡300 mg/24 h after 20 weeks,
gestation. Patients with severe preeclampsia also met at
least one of the following criteria: blood pressure
>160/110 mmHg on at least two occasions, protein-
uria of >5 g in 24-h urine collection, eclampsia,
HELLP (hemolysis, elevated liver enzymes and low
platelet count) syndrome (total bilirubin concentration
>1.2 or lactate dehydrogenase activity >600 IU/l;
aspartate aminotransferase >70 IU/l; <100,000 plate-
lets/dl), unremitting headache, right upper-quadrant
pain or ultrauterine growth at <5th percentile.
MIF ELISA
The concentrations of MIF in serum samples were
measured by a colorometric sandwich ELISA. ELISA
plates were coated with 100 ll/well of antihuman MIF
monoclonal antibody (2.0 lg/ml) (R&D Systems) and
incubated overnight at room temperature. The plates
were washed three times with washing solution (10 mM
PBS, pH 7.4, 0.05% Tween 20), blocked by adding
300 ll of blocking solution (10 mM PBS, pH 7.4, 2%
bovine serum albumin) and incubated at room temper-
ature for 1.5 h. After washing three times, the samples
diluted 1:1 in Tris-buﬀered saline-BSA (20 mM Tris-
HCl, 150 mM NaCl, 1%BSA, 0.05% Tween) were
added in triplicate (100 ll/well) and incubated for 2 h at
room temperature. The plates were then washed three
times and 100 ll of biotinylated goat antihuman MIF
polyclonal antibody (200 ng/ml) (R&D Systems) was
added to each well and incubated for 2 h at room tem-
perature. The plates were washed again and strepatavi-
din horseradish peroxidase (Zymed, San Francisco, CA,
USA) was added to each well and incubated for 20 min
at room temperature. The plates were washed and 3,3¢,
5,5¢-tetramethylbenzidine (Zymed) was added. After
20 min, the reaction was stopped by adding H2SO4. The
absorbance was measured at 450 nm using an ELISA
microplate reader. MIF concentrations were expressed
as nanogram per millimeter. The mean coeﬃcient of
variation of the assay was 4.7%.
Statistics
The data were analysed with the Mann–Whitney rank
sum test using the SigmaStat (SPSS Inc, Chi-
cago,IL,USA) software package. Data are presented by
box plots (Fig. 1), indicating the median value (line in
the box), the 75th and 25th percentiles (limits of box)
and the 10th and 90th percentiles (upper and lower
horizontal bars), respectively.
Results
Our analysis indicated that the circulatory concentra-
tions of MIF were elevated in normal pregnancy (med-
ian=10.1 ng/ml) when compared to samples obtained
from normal non-pregnant female blood donors (med-
ian=1.7 ng/ml). Although the levels of circulatory MIF
were slightly higher in samples obtained from healthy
male blood donors (2.8 ng/ml), these were not signiﬁ-
cantly diﬀerent from those of female blood donors. Our
analysis indicated that a moderate, but not signiﬁcant,
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Fig. 1 Box plot illustrating circulatory MIF concentrations in non-
pregnant healthy female blood donors (NON), normotensive
control cases (CON), cases with mild preeclampsia (mPE) or severe
preeclampsia (sPE)
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increase in the concentration of circulatory MIF oc-
curred from the ﬁrst to the third trimester of pregnancy
(Table 1).
As circulatory MIF concentrations have recently
been reported to be elevated in cases with preeclamp-
sia, we next examined this aspect. For our analysis, we
used samples obtained from 20 cases with a mild form
of this disorder, as well as a further 20 samples from
cases with a severe form of this disorder. The latter
group included cases with HELLP syndrome and
eclampsia. Our analysis indicated that circulatory MIF
concentrations were not signiﬁcantly diﬀerent in the
cases with mild or severe preeclampsia when compared
to the matched normotensive control group (Table 2,
Fig. 1).
Discussion
Elevated concentrations of MIF have recently been re-
ported to occur in pregnancies with manifest pre-
eclampsia [8]. These data are in contrast to those we
have observed in our current analysis, where we ob-
served no discernible elevation in MIF levels in cases
with preeclampsia when compared to matched normo-
tensive controls. While we observed similar MIF con-
centrations in our cases with preeclampsia when
compared to those observed by Todros et al. [8] (9.7 ng/
ml in mild preeclampsia and 9.9 ng/ml in severe pre-
eclampsia vs. 12.74 ng/ml), the same was not true for
samples from normal healthy pregnancies. In these cases
we consistently observed MIF concentrations of around
10 ng/ml in all 80 samples from normal pregnancies,
which are considerably higher than those observed by
Todros et al. [8] in their control cohort (median=5.3 ng/
ml). Although it is possible that this disparity may be
attributable to the diﬀerence in sample sizes between the
two studies, our data is obtained from a very large co-
hort (n=80 samples from normal pregnancies and n=40
samples from pregnancies with manifest preeclampsia).
Consequently, our data do suggest that circulatory MIF
concentrations are elevated in pregnancy, when com-
pared to non-pregnant controls, but are not further
elevated under conditions of preeclampsia.
These ﬁndings may be noteworthy as the elevated
presence of MIF throughout pregnancy implies that its
continued presence is important. As MIF possesses
pleotropic activities, it is possible that these may include
its ability to promote neovascularisation, which is cer-
tainly of importance for eﬃcient placentation [3, 6].
However, it is also probable that in pregnancy, MIF
may function in its immunemodulatory capacity by
promoting a condition of immune privilege, especially
in its ability to inhibit the cytolytic activity of CD8 T
cells and NK cells [2]. In this manner it can be pos-
tulated that the elevated presence of MIF in pregnancy
may prevent the destruction of semi-allogeneic placen-
tal tissue by inadvertently activated maternal immune
eﬀector cells. Furthermore, as there is little evidence of
the increased activity of maternal NK or CD8 T cells
in preeclampsia [9], this may help to explain our
observation that MIF levels are not altered in this
disorder, in that there is no increased requirement for
MIF activity in preeclampsia.
As such our data provide evidence for the involve-
ment of another factor in the complex regulatory
mechanisms maintaining the balance between the
maternal and fetal immune systems to ensure a beneﬁcial
pregnancy outcome. However, since we also detected
MIF expression in the ovary (data not shown), another
immune privileged site [3, 12], it is likely that MIF may
play a general role in the maintenance of this immuno-
logical phenomenon, apart from its apparent role in
pregnancy [6].
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Table 1 Concentrations of
MIF in normal non-pregnant
donors and throughout
pregnancy
Values are given as median and
range in brackets
Healthy female
blood donors
Healthy male
blood donors
First trimester
of pregnancy
Second trimester
of pregnancy
Third trimester
of pregnancy
n 20 20 8 32 20
Gestational age N/A N/A 11+6 16+0 31+5
MIF concentration
(ng/ml)
1.7 (0.1–4.5) 2.8 (1.1–5.4) 9.2 (9.9–12.7) 9.5 (4.9–15.1) 9.9 (6.9–13.3)
Table 2 MIF concentrations
and clinical characteristics of
the preeclampsia study groups
and matched normotensive
control cohort
Values are given as median and
range in brackets
Normotensive
controls
Mild
preeclampsia
Severe
preeclampsia
n 20 20 20
Systolic blood pressure 127(110–134) 161(150–191) 193(160–239)
Diastolic blood pressure 75 (67–87) 102 (96–108) 120 (110–140)
Fetal weight at birth (g) 3,264 (2024–3940) 2,645 (1151–3455) 1,964,(1144–3135)
MIF concentration (ng/ml) 10.1 (7.3–15.3) 9.7 (1.4–16.9) 9.9 (6.2–16.3)
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